S-1: Acurx Pharma Registers 585K Shares for Lincoln Park Resale

Acurx Pharmaceuticals filed an S-1 registration statement for the resale of up to 585,000 common shares by Lincoln Park Capital Fund, LLC, enabling the company to potentially raise an additional $9.0 million.

Summary

• Acurx Pharmaceuticals, Inc. filed an S-1 registration statement for the resale of up to 585,000 shares of common stock by Lincoln Park Capital Fund, LLC.
• These shares are part of a Purchase Agreement dated May 8, 2025, where Lincoln Park committed to purchase up to $12.0 million of common stock.
• The company has already received $3.0 million from sales to Lincoln Park under a prior registration statement.
• Acurx may receive up to an additional $9.0 million in gross proceeds from future sales to Lincoln Park under the Purchase Agreement.
• The selling stockholder (Lincoln Park) will pay all brokerage fees and commissions; Acurx will pay registration expenses.
• A 1-for-20 reverse stock split was effected on August 4, 2025.
• The total number of authorized common shares was increased from 200,000,000 to 250,000,000 on September 22, 2025.
• As of October 14, 2025, there were 2,081,323 shares of common stock outstanding.
• The last reported sale price of common stock on Nasdaq on October 17, 2025, was $6.80 per share.
• Acurx is an emerging growth company and a smaller reporting company, subject to reduced reporting requirements.

Sentiment

Score: 5

Explanation: The filing is primarily procedural, registering shares for resale under an existing financing agreement. While it confirms access to potential capital, it also highlights significant dilution risks and the ongoing need for substantial additional financing, balancing out the sentiment.

Positives

• Secures potential access to an additional $9.0 million in capital through the Purchase Agreement with Lincoln Park, providing funding for working capital and general corporate purposes.
• The company retains discretion over the timing and amount of sales to Lincoln Park, allowing flexibility in capital raising.
• Lincoln Park is prohibited from short-selling or hedging Acurx's common stock during the term of the Purchase Agreement.
• Stockholder approval was obtained on July 17, 2025, for the issuance of shares exceeding 19.99% of outstanding shares to Lincoln Park, demonstrating shareholder support for the financing mechanism.

Negatives

• The sale of common stock to Lincoln Park and subsequent resale by Lincoln Park will cause substantial dilution to existing stockholders.
• The actual gross proceeds from sales to Lincoln Park may be substantially less than the $9.0 million remaining commitment, depending on market prices, potentially affecting liquidity.
• The anticipation of future sales by Lincoln Park could cause the stock price to decline or make it more difficult for Acurx to raise capital from other sources.
• Management has broad discretion over the use of proceeds, which may not always align with investor expectations or improve financial condition/market value.
• The company will need to raise substantial additional capital beyond the $12.0 million from Lincoln Park to fund operations and execute its business strategy.

Risks

• The sale of common stock to Lincoln Park may cause dilution, and the subsequent sale of shares by Lincoln Park, or the perception of such sales, could cause the price of common stock to fall.
• It is not possible to predict the actual number of shares to be sold to Lincoln Park or the actual gross proceeds, as the purchase price fluctuates with market prices.
• If the market price of common stock is low, Acurx may need to sell more shares to Lincoln Park to achieve the desired proceeds, leading to greater dilution.
• Acurx may not have access to the full $12.0 million available under the Purchase Agreement due to market conditions or the Beneficial Ownership Cap (Lincoln Park cannot beneficially own more than 4.99% or 9.99% upon notice).
• The company requires additional financing to sustain operations, and without it, may not be able to continue.
• The terms of subsequent financings may adversely impact stockholders.
• Management's broad discretion over the use of proceeds may not be effective or align with investor interests.
• Decreased disclosures due to emerging growth company and smaller reporting company status may make it harder for investors to analyze results and prospects.
• Investment in securities involves a high degree of risk and could result in a loss of the entire investment.
• The company's ability to obtain and maintain regulatory approval for product candidates (ibezapolstat) is uncertain.
• Ability to successfully commercialize and market product candidates is uncertain.
• Reliance on third-party suppliers, manufacturers, and service providers.
• Uncertainty regarding market size, opportunity, and growth potential for product candidates.
• Ability to build sales and marketing capabilities or find collaborative partners.
• Ability to obtain funding for operations.
• Risks related to the initiation, timing, progress, and results of preclinical studies and clinical trials.
• Timing of anticipated regulatory filings and data availability from clinical trials.
• Accuracy of estimates regarding expenses, capital requirements, and financing needs.
• Ability to retain key professionals and hire additional qualified personnel.
• Ability to advance product candidates into and successfully complete clinical trials.
• Ability to recruit and enroll suitable patients in clinical trials and timing of enrollment.
• Timing or likelihood of achieving scientific, clinical, regulatory, and product development objectives.
• Pricing and reimbursement of product candidates, if approved.
• Rate and degree of market acceptance of product candidates, if approved.
• Implementation of business model and strategic plans.
• Scope of intellectual property protection.
• Developments relating to competitors and the industry.
• Impact of major public health concerns (e.g., coronavirus, other pandemics) on clinical trials, business operations, and funding.
• Effects of disruptions and volatility in credit and financial markets (e.g., Russia-Ukraine conflict, Middle East conflict).
• Volatility of the price of common stock.
• Ability to comply with Nasdaq listing requirements.
• Anti-takeover provisions in the certificate of incorporation and bylaws may delay or discourage acquisitions.
• Indemnification of directors and officers may adversely affect stockholders if the company pays settlement and damage awards.

Future Outlook

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, targeting Gram-positive bacteria identified as priority pathogens by WHO, CDC, and FDA. The company aims to obtain and maintain regulatory approval for its product candidates, successfully commercialize them, and secure additional funding to advance its research and development programs and execute its business strategy.

Management Comments

• Management will have broad discretion over the use of the net proceeds from sales of shares of common stock to Lincoln Park, and investors may not agree with how the proceeds are used, or the proceeds may not be used effectively.

Industry Context

Acurx Pharmaceuticals operates in the biopharmaceutical industry, specifically focusing on developing novel antibiotics to combat the global crisis of Antimicrobial Resistance (AMR). Its pipeline targets Gram-positive bacteria, including priority pathogens identified by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA). This focus aligns with a critical unmet medical need in the infectious disease sector, where traditional antibiotics are losing effectiveness.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience substantial dilution from the sale of common stock to Lincoln Park and subsequent resale. The stock price may be negatively impacted by these sales or the anticipation of them. Existing stockholders will see their percentage ownership decrease.
• Company (Acurx Pharmaceuticals): Gains access to up to $9.0 million in additional capital for working capital and general corporate purposes, including R&D. However, it faces the risk of not accessing the full amount and needing further substantial financing.
• Lincoln Park Capital Fund, LLC: Acts as a selling stockholder, acquiring shares at a discount and reselling them in the market. Benefits from the purchase agreement terms.
• Employees: No direct impact mentioned, but continued funding supports ongoing operations and R&D, which could indirectly benefit employees through job security and project continuity.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Continue to draw down on the remaining $9.0 million commitment from Lincoln Park under the Purchase Agreement, at management's discretion.
• File additional registration statements if more than the currently registered 585,000 shares are to be sold to Lincoln Park to reach the full $9.0 million.
• Advance research and development programs for antibiotic product candidates.
• Seek regulatory approvals for ibezapolstat and other product candidates.
• Secure substantial additional capital beyond the Lincoln Park agreement to fund ongoing operations and strategic initiatives.

Key Dates

Recommendation

The S-1 filing is a procedural step to enable Acurx Pharmaceuticals to access an existing equity line of credit with Lincoln Park. While it provides a potential source of up to $9.0 million in additional capital, which is crucial for a late-stage biopharmaceutical company, the mechanism involves significant dilution for existing shareholders. The company's need for 'substantial additional capital' beyond this $12.0 million facility indicates ongoing financial challenges. The reverse stock split, while potentially helping with Nasdaq compliance, does not fundamentally change the company's valuation or operational risks. Given the high dilution potential and the continued need for financing, coupled with the inherent risks of biopharmaceutical development, a 'hold' recommendation is appropriate. Investors should monitor the company's progress in clinical trials and its ability to secure non-dilutive or less dilutive financing before considering further investment.

Keywords

Acurx Pharmaceuticals, ACXP, SEC Filing, S-1, Common Stock, Resale, Lincoln Park Capital, Equity Financing, Dilution, Biopharmaceutical, Antibiotics, Gram-positive bacteria, Clostridioides difficile, MRSA, Vancomycin resistant Enterococcus, Drug-resistant Streptococcus pneumoniae, Reverse Stock Split, Capital Raise, Nasdaq Capital Market, Emerging Growth Company, Smaller Reporting Company, Risk Factors